• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

功能评估简短测试(FAST):接受抗抑郁治疗的重度抑郁症患者的临床有意义反应阈值。

The Functioning Assessment Short Test (FAST): Clinically meaningful response threshold in patients with major depressive disorder receiving antidepressant treatment.

机构信息

H. Lundbeck A/S, Valby, Denmark.

H. Lundbeck A/S, Valby, Denmark.

出版信息

J Affect Disord. 2024 Oct 15;363:634-642. doi: 10.1016/j.jad.2024.07.018. Epub 2024 Jul 15.

DOI:10.1016/j.jad.2024.07.018
PMID:39019235
Abstract

BACKGROUND

Functional impairment is common in patients with major depressive disorder (MDD). The Functioning Assessment Short Test (FAST) provides a detailed clinician-rated assessment of functioning across multiple aspects of daily life. This study aimed to establish clinically relevant response thresholds for the FAST in patients with MDD receiving antidepressant treatment.

METHODS

Data were derived from three 8-week clinical trials of antidepressant therapy in patients with MDD that included assessment of functioning using the FAST as a pre-specified endpoint. The minimal clinically important difference (MCID) and threshold for response in terms of change in FAST total score were determined using anchor-based methods.

RESULTS

After 8 weeks of antidepressant treatment, the mean reduction in FAST total score in patients considered clinically minimally improved (Clinical Global Impression-Improvement [CGI-I] score of 3) was 7-9 points (20 % reduction). The threshold for functional response (reduction in FAST total score from baseline in patients with a CGI-I score of ≤2 at week 8) was 16-19 points (50 % reduction). The threshold for functional response was higher in patients with MDD and comorbid generalized anxiety disorder than in those with MDD alone (mean reduction in FAST total score at 8 weeks: 26 points [63 %]).

LIMITATIONS

Short-term studies.

CONCLUSIONS

These results provide further validation of the FAST for assessing functioning in patients with MDD. In patients with MDD, the suggested MCID for FAST total score is 7-9 points and the proposed threshold for response is a reduction from baseline of approximately 50 %.

摘要

背景

在患有重度抑郁症(MDD)的患者中,功能障碍很常见。功能评估简短测试(FAST)提供了对日常生活多个方面的功能进行详细的临床评估。本研究旨在为接受抗抑郁治疗的 MDD 患者建立 FAST 的临床相关反应阈值。

方法

数据来自三项为期 8 周的抗抑郁治疗临床试验,这些试验包括使用 FAST 作为预先指定的终点评估功能。使用基于锚定的方法确定 FAST 总分变化的最小临床重要差异(MCID)和反应阈值。

结果

在 8 周的抗抑郁治疗后,被认为临床轻度改善的患者(临床总体印象改善量表 [CGI-I] 评分为 3)的 FAST 总分平均降低 7-9 分(20%的降低)。功能反应的阈值(8 周时 CGI-I 评分≤2 的患者 FAST 总分从基线的降低)为 16-19 分(50%的降低)。与仅患有 MDD 的患者相比,患有 MDD 和共患广泛性焦虑症的患者的功能反应阈值更高(8 周时 FAST 总分的平均降低:26 分[63%])。

局限性

短期研究。

结论

这些结果进一步验证了 FAST 用于评估 MDD 患者的功能。在 MDD 患者中,FAST 总分的建议 MCID 为 7-9 分,建议的反应阈值为基线降低约 50%。

相似文献

1
The Functioning Assessment Short Test (FAST): Clinically meaningful response threshold in patients with major depressive disorder receiving antidepressant treatment.功能评估简短测试(FAST):接受抗抑郁治疗的重度抑郁症患者的临床有意义反应阈值。
J Affect Disord. 2024 Oct 15;363:634-642. doi: 10.1016/j.jad.2024.07.018. Epub 2024 Jul 15.
2
The Motivation and Energy Inventory (MEI): Analysis of the clinically relevant response threshold in patients with major depressive disorder and emotional blunting using data from the COMPLETE study.动机与能量量表(MEI):利用COMPLETE研究的数据对重度抑郁症和情感迟钝患者的临床相关反应阈值进行分析。
J Affect Disord. 2023 Feb 15;323:547-553. doi: 10.1016/j.jad.2022.11.033. Epub 2022 Nov 14.
3
Validation of the Oxford Depression Questionnaire: Sensitivity to change, minimal clinically important difference, and response threshold for the assessment of emotional blunting.牛津抑郁问卷的验证:对情绪迟钝评估的变化敏感性、最小临床重要差异和反应阈值。
J Affect Disord. 2021 Nov 1;294:924-931. doi: 10.1016/j.jad.2021.07.099. Epub 2021 Jul 31.
4
Novel Augmentation Strategies in Major Depression.重度抑郁症的新型强化治疗策略
Dan Med J. 2017 Apr;64(4).
5
Minimal clinically important change in the MADRS anhedonia factor score: A pooled analysis of open-label studies with vortioxetine in patients with major depressive disorder.MADRS 快感缺失因子评分的最小临床有意义变化:在伴有重性抑郁障碍的患者中,使用沃替西汀进行开放性研究的汇总分析。
J Affect Disord. 2024 Oct 15;363:430-435. doi: 10.1016/j.jad.2024.07.070. Epub 2024 Jul 18.
6
[Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].米那普明和文拉法辛灵活剂量(最高200毫克/天)用于门诊治疗中度至重度成人重度抑郁症:一项为期24周的随机、双盲探索性研究
Encephale. 2009 Dec;35(6):595-604. doi: 10.1016/j.encep.2009.10.011.
7
Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.巴米谷氨酸辅助治疗重性抑郁症的疗效和安全性:一项随机临床试验。
JAMA Psychiatry. 2016 Jul 1;73(7):675-84. doi: 10.1001/jamapsychiatry.2016.0838.
8
Evaluation of functional health and well-being in patients receiving levomilnacipran ER for the treatment of major depressive disorder.对接受左旋米那普明缓释片治疗重度抑郁症患者的功能健康和幸福感的评估。
J Affect Disord. 2015 Jan 1;170:230-6. doi: 10.1016/j.jad.2014.09.005. Epub 2014 Sep 10.
9
Dimensions of anxiety in Major depressive disorder and their use in predicting antidepressant treatment outcome: an iSPOT-D report.重性抑郁障碍中的焦虑维度及其在预测抗抑郁治疗结局中的应用:iSPOT-D 报告。
Psychol Med. 2020 Apr;50(6):1032-1042. doi: 10.1017/S0033291719000941. Epub 2019 Apr 26.
10
Efficacy outcomes in the MDD-1 India study: First episode major depressive disorder outcomes in antidepressant-treated real-world patients in India.MDD - 1印度研究中的疗效结果:印度接受抗抑郁药治疗的现实世界患者的首发重度抑郁症结果。
J Psychopharmacol. 2020 Oct;34(10):1098-1104. doi: 10.1177/0269881120932759. Epub 2020 Jul 20.

引用本文的文献

1
Insights on the cognitive enhancement effect of desvenlafaxine in major depressive disorder.度洛西汀对重度抑郁症认知增强作用的见解。
Ann Gen Psychiatry. 2025 Mar 19;24(1):16. doi: 10.1186/s12991-025-00552-2.